StockStory flags Boston Scientific, questions Tecnoglass and Hayward
StockStory, a financial research provider, published a report identifying Boston Scientific as a stock under $50 with significant upside potential, while expressing caution regarding Tecnoglass and Hayward. The analysis focuses on companies trading between $10 and $50, a range the firm argues often contains businesses that have survived early challenges but may still face unproven business models.
StockStory, a financial research provider, published a report identifying Boston Scientific as a stock under $50 with significant upside potential, while expressing caution regarding Tecnoglass and Hayward. The analysis focuses on companies trading between $10 and $50, a range the firm argues often contains businesses that have survived early challenges but may still face unproven business models.
Tecnoglass, the first Colombian company to trade on NASDAQ, manufactures architectural glass, windows, and aluminum products. The report cites concerns over the company's profitability, noting that earnings per share fell by 5.5% annually over the past two years. Additionally, free cash flow margin declined by 11.5 percentage points over the last five years, a trend StockStory attributes to increased investments aimed at defending market position. Shrinking returns on capital suggest that rising competition is impacting profitability. At a share price of $38.59, Tecnoglass trades at 13.6x forward P/E.
Hayward, which manufactures residential and commercial pool equipment and accessories, is credited with introducing the first variable-speed pool pump. StockStory highlights that Hayward’s sales were flat over the last five years, indicating a failure to expand during this cycle. Estimated sales growth of 3% for the next 12 months implies a slowdown in demand from the previous two-year trend. Falling earnings per share over the last five years has also raised concerns among investors. With a stock price of $12.04, Hayward carries a valuation ratio of 13x forward P/E.
In contrast, StockStory presents a positive outlook for Boston Scientific, which develops medical devices for minimally invasive procedures across cardiovascular, urological, neurological, and gastrointestinal specialties. Founded in 1979, the company has demonstrated organic revenue growth averaging 15.8% over the past two years, allowing expansion without risky acquisitions. Annual earnings per share growth of 18.6% over the last five years outpaced revenue gains, indicating highly profitable incremental sales. Free cash flow margin improved by 12.3 percentage points over the same five-year period, providing resources for growth initiatives, share repurchases, or dividends. Boston Scientific trades at $45.29 per share, representing a 14x forward P/E.